Under normal physiological conditions, soluble ACE2 is difficult to detect in patient plasma [49,50]; however, in patients with severe COVID-19, increased concentrations of soluble ACE2 are observed which correlate with pathoprogression [51,52,53,54]. This evidence concerns the gene ACE2 and COVID-19.